Marijuana and multiple sclerosis

被引：7

作者：

Goodin, D ^{[1
]}

机构：

[1] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA

来源：

LANCET NEUROLOGY | 2004年 / 3卷 / 02期

关键词：

D O I：

10.1016/S1474-4422(03)00655-0

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

引用

页码：79 / 80

页数：2

共 11 条

[1]

ASHWORTH B, 1964, PRACTITIONER, V192, P540

[2]

CHECK WA, 1979, JAMA-J AM MED ASSOC, V241, P2476

[3]

ElSohly, 1995, ZAGAZIG J PHARM SCI, V4, P1, DOI DOI 10.21608/ZJPS.1995.169714

[4] Cannabis and the brain [J].

Iversen, L .

BRAIN, 2003, 126 :1252-1270

[5] Safety, tolerability, and efficacy of orally administered cannabinoids in MS [J].

Killestein, J ;

Hoogervorst, ELJ ;

Reif, M ;

Kalkers, NF ;

van Loenen, AC ;

Staats, PGM ;

Gorter, RW ;

Uitdehaag, BMJ ;

Polman, CH .

NEUROLOGY, 2002, 58 (09) :1404-1407

[6] EFFECT OF CANNABINOIDS ON SPASTICITY AND ATAXIA IN MULTIPLE-SCLEROSIS [J].

MEINCK, HM ;

SCHONLE, PW ;

CONRAD, B .

JOURNAL OF NEUROLOGY, 1989, 236 (02) :120-122

[7] Cannabis use as described by people with multiple sclerosis [J].

Page, SA ;

Verhoef, MJ ;

Stebbins, RA ;

Metz, LM ;

Levy, JC .

CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES, 2003, 30 (03) :201-205

[8] Cannabinoids and multiple sclerosis [J].

Pertwee, RG .

PHARMACOLOGY & THERAPEUTICS, 2002, 95 (02) :165-174

[9]

Smith Paul F, 2002, Curr Opin Investig Drugs, V3, P859

[10]

UNGERLEIDER J T, 1987, Advances in Alcohol and Substance Abuse, V7, P39

← 1 2 →